Table 2. Characteristics of the sera and plasmas used in this study.
| Sera / Plasmas | Number | Median IHA | Mean / Median Age | Sexb | Diabetes | Blood Culture | Mean / Median ADM Samples# |
|---|---|---|---|---|---|---|---|
| sera melioidosis positive, week 0: total | 75 | 160 | 55 / 56 | 24 F / 51 M | 51 pos / 24 neg | 51 pos / 24 neg | 5 / 5 |
| sera melioidosis positive, week 0: survivors | 40 | 320 | 53 / 54.5 | 10 F / 30 M | 30 pos / 10 neg | 20 pos / 20 neg | 6 / 5 |
| sera melioidosis positive, week 0: non-survivors | 35 | 80 | 57 / 57 | 14 F /21 M | 21 pos / 14 neg | 31 pos / 4 neg | 5 / 5 |
| sera melioidosis positive, week 12 | 50 | 320 | 54 / 54 | 14 F / 36 M | 35 pos / 15 neg | 24 pos /26 neg | 5 / 5 |
| sera melioidosis positive, week 52 | 46 | 80 | 53.5 / 54 | 13 F / 33 M | 32 pos / 14 neg | 22 pos / 24 neg | 5 / 5 |
| sera healthy, endemic (Ubon Ratchathani) and non endemic (Bangkok, Thailand) | 100 | 10 | 46 / 44 | 47 F / 53 M | 74 pos / 26 neg | - | - |
| sera healthy, non-endemic (Greifswald, Germany) | 25 | n.d. | 37 / 33 | 12 F / 13 M | n.d. | - | - |
| sera bacteremia/fungemia, non-endemic (Greifswald, Germany) | 60 | n.d. | 59 / 62 | 22 F / 38 M | n.d. | 60 pos / 0 neg | 9.4 / 5.5a |
| plasmas melioidosis negative | 25 | n.d. | 52 / 51 | 8 F / 17 M | 0 pos / 25 neg | - | - |
| plasmas melioidosis positive: total | 25 | n.d. | 54 / 54 | 8 F / 17 M | 18 pos / 7 neg | 15 pos / 10 neg | 7 / 6 |
| plasmas melioidosis positive: survivor | 15 | n.d. | 52 / 54 | 4 F / 11 M | 11 pos / 4 neg | 5 pos / 10 neg | 7 / 8 |
| plasmas melioidosis positive: non-survivor | 9 | n.d. | 57 / 62 | 4 F / 5 M | 6 pos / 3 neg | 9 pos / 0 neg | 6 / 6 |
| plasmas melioidosis positive: unknown outcome | 1 | n.d. | 52 | M | pos | pos | 6 |
n.d.–not determined
# ADM—Number of days from date of hospital admission to date of serum/plasma sample draw.
a Number of days from date of positive blood culture to date of serum sample draw.
b F–female, M—male